A Study to Evaluate the Safety and Effect of TO-O-1007 Intravitreal Implant in Subjects With Geographic Atrophy

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Geographic Atrophy Due to Age-Related Macular Degeneration

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Retina & Eye Consultants, Hurstville, New South Wales (nsw), Australia
Contact: Study coordinator (Amanda Feeney) · amanda.feeney@retinaandeye.com.au · +61 2 9570 1622
Contact: Principal Investigator (Dr. Derek Chan)
Sydney Retina Clinic & Day Surgery, Sydney, New South Wales (nsw), Australia
Contact: Study coordinator (Lifei Chen) · Lifei.chen@cureos.com.au · +61 2 9221 3755
Contact: Principal Investigator (Dr. Andrew Chang)
Launceston Eye Doctors, Launceston, Tasmania (tas), Australia
Contact: Study coordinator (Karen Hutt) · khutt@launcestoneyedoctors.com.au · +61 3 6334 0000
Contact: Principal Investigator (Dr. Tze-Yo Toh)

Study leads

Dr. Andrew Chang
Principal Investigator
Sydney Retina Clinic & Day Surgery

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

Age-Related Macular Degeneration

Abroad (travel likely)RecruitingPHASE1

Phoenix, United States · Los Angeles, United States